CNBC on MSN24d
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions – NBC Los Angeles
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
MedPage Today2h
Online Sellers of Compounded GLP-1s Often Don't Mention Risks
Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...
WDRB20h
Louisville pharmacy dispensing compounded weight loss drugs in effort to address shortage
Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...
pharmaphorum11d
Novo Nordisk asks FDA not to allow GLP-1 compounding
Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...
BioPharma Dive2h
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
How Trump’s Greenland demands could impact Ozempic costs
President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...
BioSpace11d
Novo Launches Citizen Petition to Block Compounded Victoza
In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...
NBC Bay Area24d
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
Many compounding pharmacies make unbranded versions of semaglutide, which has been on the U.S. market — and in short supply — for much longer than tirzepatide. But an end to the shortage may ...